backtop


Print

The weekly injection removed 80 percent of senile plaques that cause Alzheimer's

Canadian researchers have come one giant step closer to finding treatment for those with Alzheimer's disease, and even a preventative vaccine.

The team of researchers hail from Université Laval, CHU de Québec, and pharmaceutical firm GlaxoSmithKline (GSK), and was led by Dr. Serge Rivest, professor at Université Laval's Faculty of Medicine and researcher at the CHU de Québec research center.

A key part of Alzheimer's disease is the production of a toxic molecule called amyloid beta. The body's defenders, called microglial cells, cannot eliminate amyloid beta, and that's when senile plaques are formed.

But the new study gives the brain's immune cells a boost through monophosphoryl lipid A, called MPL, which is a vaccine that has already been proven safe through its use with GSK.

After giving mice with Alzheimer's symptoms weekly injections of MPL for 12 weeks, about 80 percent of senile plaques were eliminated. Also, the mice showed improvement in cognitive function.

According to the team, the MPL injection could not only slow the progression of the disease in patients already showing symptoms, but also be used as a preventative vaccine for those at risk.

Last September, the cancer drugs erlotinib (Tarceva) and gefitinib (Iressa) were used to cure Alzheimer's in fruit flies and rats.

Source: Science Daily





"It's okay. The scenarios aren't that clear. But it's good looking. [Steve Jobs] does good design, and [the iPad] is absolutely a good example of that." -- Bill Gates on the Apple iPad






Most Popular Articles2nd Generation August Smart Lock – Now with Apple HomeKit Features
September 18, 2017, 7:00 AM
iSO 11 is Almost Ready:
September 19, 2017, 7:48 AM
Intel Coffee Lake release date
September 10, 2017, 6:07 AM
iOS 11 Arrives in 2 Days – Here is What You Get.
September 17, 2017, 6:59 AM
We will Get 5G Phones in 2019
September 19, 2017, 6:49 AM

Latest Blog Posts






botimage
Copyright 2017 DailyTech LLC. - RSS Feed | Advertise | About Us | Ethics | FAQ | Terms, Conditions & Privacy Information | Kristopher Kubicki